Navigation Links
ThyroTest

ProductsThyroTest
Company ThyroTec Inc.
Item ThyroTest
Features 
Description ThyroTest by ThyroTec, Inc. is a rapid immunoassay, similar to a rapid pregnancy test. By using 2 drops of blood from a finger stick and 5 drops of diluent, a qualitative TSH level is inicated in minutes.
Info ThyroTec Inc.
Customer Service: (800) 257-9525
Web site: http://www.thyrotest.com/index.html

Related medicine products :

1. ThyroTest® TSH
TAG: ThyroTest
CenterPointLock Stoma Cap
CenterPointLock Sterile Drainable Kits
CenterPointLock Non-Sterile Urostomy Kits
CenterPointLock Pre-Sized Convex FlexWear Skin Barrier
Medicine Products:
(Date:12/3/2008)...Netherlands, and LOS ANGELES, Dec. 3 /PRNewswire/ ...r as the President of Bugaboo,Americas. Boiler ha...rica for,the past 5 years. "Kari Boiler has the B...t a great team player with the vision that Bugaboo...Muis, CEO of Bugaboo International. , (Phot...
(Date:12/3/2008)...Dec. 3 The American Soc... School Student Symposium at the San Francisco Mar...8:00 a.m. PST. The symposium, which encourages an ...nd medical research, is held in conjunction with t...nts will have the opportunity to explore research ...
(Date:12/3/2008)...Dec. 3 The American Soc...essional society of blood specialists, will recogn...es and the Deputy Director of the National Heart, ...s to promote biomedical research. The Public Servi...e Society,s 50th Annual Meeting in San Francisco, ...
(Date:12/3/2008)....J., Dec. 3 MedQuist Inc. (Nasdaq:...ce Organization (MTSO) in the world, is pleased to...ial legal matters , , Resolution of the DO...d, the Company received an administrative HIPAA su...ment of Justice ("DOJ") on December 17, 2004. The ...
Breaking Medicine News(10 mins):Health News:Kari Boiler Named President of Bugaboo Americas 2Health News:ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 2Health News:ASH Honors Speaker of the House Nancy Pelosi and NHLBI Deputy Director Susan Shurin, MD, for Their Public Service, Leadership, and Commitment to Biomedical Research 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6
...ording to a recent study conducted by the research...cular Biology Laboratory (EMBL) and the Max Planck...nd the structural image of a protein needed for th...by the drug companies. Tuberculosis is one of the...
... Delhi. Serious differences cropped up among the ...eir anti-reservation// stir in view of a stern war...tely. A section of the protestors, mostly residen... the strike to honor the apex court direction, whi...
...nghai doctors were perplexed with two-month-old bo...lueless about the cause of his deformity.// The b...ntre, one of China's top hospitals for treating co...were unsure which of his two left arms was his str...
...phetess Lucy Nduta of the Salvation Healing Minist...uced before court on charges of swindling six peop...elling the people that they would be cured of HIV/...ncipal Magistrate, Margaret Muigai, denied her bai...
Other Medicine News:
(Date:12/3/2008)... demonstrating potential in newly diagnosed patien...featured in two oral sessions at ASH , , - ...ally transfused patients by significantly reducing...- New long-term data from major independent breast...urgery treatment strategy, Femara vs. tamoxifen ,...
(Date:12/3/2008)...ewswire/ -- Roche today announced that the U.S. Fo...her guidance on the requirements for the Biologics...umab), the first interleukin-6 (IL-6) receptor-inh...ent of adult patients with moderately to severely ... result of the FDA,s evolving Risk Evaluation and ...
(Date:12/3/2008)...ire-FirstCall/ -- Sangamo BioSciences, Inc.,(Nasd...de an update on milestones,achieved in 2008 and p...tor,and Analyst Briefing to be held in New York C... Sigma-Aldrich Corporation,s Research,Biotech Bus...potential of the,two companies, collaboration to ...
(Date:12/3/2008)...leviates long-term anemia and organ damage in mice..., MEMPHIS, Tenn., Dec. 3 /PRNewswire-USNewswire/...gene into mouse blood cells, scientists at St. Jud...kle cell disease pathology. In their studies, the ...entially no difference from normal mice. Although ...
Breaking Medicine Technology:More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 2Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 3Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 4Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab) 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3SEIU Launches Ad Campaign Opposing Corporate Raiders Plan to Buy Mich Nursing Homes 2782 1SEIU Launches Ad Campaign Opposing Corporate Raiders Plan to Buy Mich Nursing Homes 2782 2Rat Study Gets at Root of Nicotine Addiction 2780 1Rat Study Gets at Root of Nicotine Addiction 2780 2The American Red Cross Releases Book Devoted to Your Dogs Health Because Your Dog is Counting on You 2775 1The American Red Cross Releases Book Devoted to Your Dogs Health Because Your Dog is Counting on You 2775 2PA Advocates Ask President Bush What about the Kids 3F 3F 2770 1PA Advocates Ask President Bush What about the Kids 3F 3F 2770 2
...ENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharma...n of a Phase IIa proof of,concept trial with its l...he study achieved its primary objective, the absen...al significance, and,also showed trends towards im...igraine pain at other time points. ADX10059 has,al...
...ATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scie...results of its Phase III,AIR-CF2 study evaluating ... patients with cystic fibrosis (CF) who have,pulmo...e study, a,28-day treatment course of aztreonam ly...nhaled or intravenous (IV) antibiotics versus,plac...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7